ALSO READZydus Cadila receives USFDA approval to market blood pressure drug Zydus Cadila gets final USFDA nod for hypertension drug USFDA audit finds no flaws in Cadila Healthcare Moraiya unit Cadila Healthcare hits record high on USFDA approval for Levofloxacin Zydus Cadila gets USFDA nod for high blood pressure, heart disorder drug
Drug firm Zydus Cadila on Tuesday said it has received establishment inspection report from the US health regulator for its manufacturing facility at Pharma SEZ at Ahmedabad. The plant had completed the United States Food and Drug Administration (USFDA) audit from January 16-24, 2017, Zydus Cadila said in a statement. The company's "formulations manufacturing facility at Pharma SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA signifying the successful closure of the audit", it added. Shares of Cadila Healthcare, the listed entity of Zydus Group were on Tuesday trading at Rs 499.75 per scrip in the afternoon trade on BSE, down 0.26 per cent from the previous close.